多发性骨髓瘤患者骨髓CD14~+CD16~+单核细胞表达水平的研究
|
摘要
目的探讨多发性骨髓瘤(MM)患者骨髓CD14~+CD16~+单核细胞表达水平及其临床意义。方法采用流式细胞术检测多发性骨髓瘤、冒烟型骨髓瘤、淋巴浆细胞淋巴瘤/华氏巨球蛋白血症、意义未明的单克隆免疫球蛋白血症患者和对照组的骨髓CD14~+CD16~+单核细胞表达水平,统计并分析结果差异。结果多发性骨髓瘤患者骨髓CD14~+CD16~+单核细胞水平(%)明显高于冒烟型骨髓瘤、淋巴浆细胞淋巴瘤/华氏巨球蛋白血症、意义未明的单克隆免疫球蛋白血症及对照组,差异均有统计学意义(P<0.05);多部位骨质破坏多发性骨髓瘤患者的CD14~+CD16~+单核细胞比例(%)明显高于单部位骨质破坏的患者,差异有统计学意义(P<0.05)。结论骨髓CD14~+CD16~+表达水平检测可用于判断多发性骨髓瘤的溶骨病变的严重程度及其与相关疾病的鉴别诊断。
Objective To determine the levels of bone marrow CD14~+CD16~+ monocyte in patients with multiple myeloma and explore its clinical significance. Methods The levels of CD14~+CD16~+ monocytes of bone marrow samples from MM,SMM,LPL/WM,MGUS patients and healthy controls were determined by flow cytometry, and the results were analyzed.Results The level of CD14~+CD16~+ monocytes in patients with active multiple myeloma was higher than that in those with smoldering myeloma,LPL/Waldenstr 9 m macroglobulinemia,MGUS,and the healthy controls,and the differences were statistically significant(P < 0. 05); the level of CD14~+CD16~+ monocytes in patients with multiple myeloma of multiple bone destruction was higher than that in patients with single-site bone destruction,and the difference was statistically significant(P <0. 05). Conclusion The detection of bone marrow CD14~+CD16~+ monocytes level can be used to determine the severity of oateolytic lesions in multiple myeloma and used in the differential diagnosis of related diseases.
Objective To determine the levels of bone marrow CD14~+CD16~+ monocyte in patients with multiple myeloma and explore its clinical significance. Methods The levels of CD14~+CD16~+ monocytes of bone marrow samples from MM,SMM,LPL/WM,MGUS patients and healthy controls were determined by flow cytometry, and the results were analyzed.Results The level of CD14~+CD16~+ monocytes in patients with active multiple myeloma was higher than that in those with smoldering myeloma,LPL/Waldenstr 9 m macroglobulinemia,MGUS,and the healthy controls,and the differences were statistically significant(P < 0. 05); the level of CD14~+CD16~+ monocytes in patients with multiple myeloma of multiple bone destruction was higher than that in patients with single-site bone destruction,and the difference was statistically significant(P <0. 05). Conclusion The detection of bone marrow CD14~+CD16~+ monocytes level can be used to determine the severity of oateolytic lesions in multiple myeloma and used in the differential diagnosis of related diseases.
引文
[1]张之南,郝玉书,赵永强,等.血液病学[M].2版.北京:人民卫生出版社,2013:1082-1107.
[2]中国医师协会血液科医师分会,中华医学会血液学分会,中国医师协会多发性骨髓瘤专业委员会.中国多发性骨髓瘤诊治指南(2015年修订)[J].中华内科杂志,2015,54(12):1066-1070.
[3]唐洁,梁效功,薛丽,等.多参数流式细胞术在多发性骨髓瘤早期诊断中的应用价值[J].中国卫生检验杂志,2016,26(2):236-243.
[4]Rajkumar SV,Dimopoulos MA,Palumbo A,et al.International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma[J].Lancet Oncol,2014,15(12):e538-548.
[5]张建华,董春霞,任方刚,等.人破骨细胞的体外分离培养及与骨髓瘤细胞的相互作用[J].首都医科大学学报,2014,35(5):572-576.
[6]谢冰洁,冯捷,韩向龙.破骨细胞生物学特征的研究与进展[J].中国组织工程研究,2017,21(11):1770-1775.
[7]任莉荣,徐永清.破骨细胞分化机制的研究进展[J].中国骨质疏松杂志,2015,21(12):1522-1528.
[8]Ziegler-Heitbrock L,Ancuta P,Crowe S,et al.Nomenclature of monocytes and dendritic cells in blood[J].Blood,2010,116(16):e74-80.
[9]Tan D,Chng WJ,Chou T,et al.Management of multiple myeloma in Asia:resource-statified guidelines[J].Lancet Oncol,2013,14(12):e571-581.
[10]Ziegler-Heitbrock L.The CD14+CD16+blood monocytes:their role in infection and inflammation[J].J Leukoc Biol,2007,81(3):584-892.
[11]Bolzoni M,Ronchetti D,Storti P,et al.IL21R expressing CS14+CD16+monocytes expand in multiple myeloma patients leading to increased osteoclasts[J].Haematologica,2017,102(4):773-784.
[12]Kim KW,Kim HR,Kim BM,et al.Th17 cytokines regulate osteoclastogenesis in rheumatoid arthritis[J].Am J Pathol,2015,185(11):3011-3024.
[13]吴骁伟,李少晗,曹文娟.唑来膦酸影响单个核细胞向破骨细胞分化及RANK表达的研究[J].中华全科医学,2016,14(10):1644-1646.
[14]Zhan F,Hardin J,Kordsmeier B,et al.Global gene expression profiling of multiple myeloma,monoclonal gammopathy of undertermined significance,and normal bone marrow plasma cells[J].Blood,2002,99(5):1745-1757.
[15]Silbermann R,Bolzoni M,Storti P,et al.Bone marrow monocyte-/macrophage-derived activin A mediates the osteoclastogenic effect of IL-3 in multiple myeloma[J].Leukemia,2014,28(4):951-954.
[16]Freire-de-Lima L,Nardy AFFR,Ramos-Junior ES,et al.Multiple myeloma cells express key immunoregulatory cytokines and modulate the monocyte migratory response[J].Front Med,2017,27(4):1-6.
[2]中国医师协会血液科医师分会,中华医学会血液学分会,中国医师协会多发性骨髓瘤专业委员会.中国多发性骨髓瘤诊治指南(2015年修订)[J].中华内科杂志,2015,54(12):1066-1070.
[3]唐洁,梁效功,薛丽,等.多参数流式细胞术在多发性骨髓瘤早期诊断中的应用价值[J].中国卫生检验杂志,2016,26(2):236-243.
[4]Rajkumar SV,Dimopoulos MA,Palumbo A,et al.International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma[J].Lancet Oncol,2014,15(12):e538-548.
[5]张建华,董春霞,任方刚,等.人破骨细胞的体外分离培养及与骨髓瘤细胞的相互作用[J].首都医科大学学报,2014,35(5):572-576.
[6]谢冰洁,冯捷,韩向龙.破骨细胞生物学特征的研究与进展[J].中国组织工程研究,2017,21(11):1770-1775.
[7]任莉荣,徐永清.破骨细胞分化机制的研究进展[J].中国骨质疏松杂志,2015,21(12):1522-1528.
[8]Ziegler-Heitbrock L,Ancuta P,Crowe S,et al.Nomenclature of monocytes and dendritic cells in blood[J].Blood,2010,116(16):e74-80.
[9]Tan D,Chng WJ,Chou T,et al.Management of multiple myeloma in Asia:resource-statified guidelines[J].Lancet Oncol,2013,14(12):e571-581.
[10]Ziegler-Heitbrock L.The CD14+CD16+blood monocytes:their role in infection and inflammation[J].J Leukoc Biol,2007,81(3):584-892.
[11]Bolzoni M,Ronchetti D,Storti P,et al.IL21R expressing CS14+CD16+monocytes expand in multiple myeloma patients leading to increased osteoclasts[J].Haematologica,2017,102(4):773-784.
[12]Kim KW,Kim HR,Kim BM,et al.Th17 cytokines regulate osteoclastogenesis in rheumatoid arthritis[J].Am J Pathol,2015,185(11):3011-3024.
[13]吴骁伟,李少晗,曹文娟.唑来膦酸影响单个核细胞向破骨细胞分化及RANK表达的研究[J].中华全科医学,2016,14(10):1644-1646.
[14]Zhan F,Hardin J,Kordsmeier B,et al.Global gene expression profiling of multiple myeloma,monoclonal gammopathy of undertermined significance,and normal bone marrow plasma cells[J].Blood,2002,99(5):1745-1757.
[15]Silbermann R,Bolzoni M,Storti P,et al.Bone marrow monocyte-/macrophage-derived activin A mediates the osteoclastogenic effect of IL-3 in multiple myeloma[J].Leukemia,2014,28(4):951-954.
[16]Freire-de-Lima L,Nardy AFFR,Ramos-Junior ES,et al.Multiple myeloma cells express key immunoregulatory cytokines and modulate the monocyte migratory response[J].Front Med,2017,27(4):1-6.